Modeling the impact of population screening on breast cancer mortality in the United States.
暂无分享,去创建一个
Marvin Zelen | Harry J de Koning | Eric J Feuer | Kathleen A Cronin | Sylvia K Plevritis | Natasha K Stout | Donald A Berry | Clyde B Schechter | Jeanne S Mandelblatt | Nicolien T van Ravesteyn | D. Berry | E. Feuer | S. Plevritis | H. D. de Koning | M. Zelen | J. Mandelblatt | N. Stout | K. Cronin | C. Schechter | Sandra J Lee | N. V. van Ravesteyn | Sandra J. Lee | Yaojen Chang | Yaojen Chang
[1] S. Woolf,et al. The 2009 breast cancer screening recommendations of the US Preventive Services Task Force. , 2010, JAMA.
[2] Eric J Feuer,et al. The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.
[3] E. Feuer,et al. Changing patterns in breast cancer incidence trends. , 2006, Journal of the National Cancer Institute. Monographs.
[4] Dennis G. Fryback,et al. Assessing the effectiveness of health interventions for cost-effectiveness analysis , 1997, Journal of General Internal Medicine.
[5] Jennifer Cullen,et al. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. , 2006, Journal of the National Cancer Institute. Monographs.
[6] H. Nelson,et al. Screening for Breast Cancer: Systematic Evidence Review Update for the U. S. Preventive Services Task Force , 2009 .
[7] M. Zelen,et al. A stochastic model for predicting the mortality of breast cancer. , 2006, Journal of the National Cancer Institute. Monographs.
[8] Eric J Feuer,et al. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. , 2006, Journal of the National Cancer Institute. Monographs.
[9] Harry J de Koning,et al. The MISCAN-Fadia continuous tumor growth model for breast cancer. , 2006, Journal of the National Cancer Institute. Monographs.
[10] Yun Yen,et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[11] T. Lash,et al. Mammography surveillance and mortality in older breast cancer survivors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Feuer,et al. Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis. , 2006, Journal of the National Cancer Institute. Monographs.
[13] M. Rosenberg. Chapter 3: Competing Risks to Breast Cancer Mortality , 2006 .
[14] W. Lawrence,et al. Toward optimal screening strategies for older women , 2005, Journal of General Internal Medicine.
[15] Natasha K. Stout,et al. Chapter 7: The Wisconsin Breast Cancer Epidemiology Simulation Model , 2006 .
[16] H. D. de Koning,et al. Seventy‐five years is an appropriate upper age limit for population‐based mammography screening , 2006, International journal of cancer.
[17] K. Freund,et al. Mammography Use, Breast Cancer Stage at Diagnosis, and Survival Among Older Women , 2000, Journal of the American Geriatrics Society.
[18] Marvin Zelen,et al. Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms , 2009 .
[19] Ingvar Andersson,et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials , 2002, The Lancet.
[20] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[21] R. Peto,et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. , 2008, Lancet.
[22] Lurdes Y. T. Inoue,et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. , 2006, Journal of the National Cancer Institute. Monographs.
[23] Karla Kerlikowske,et al. Performance benchmarks for screening mammography. , 2006, Radiology.
[24] William Henderson,et al. Morbidity and Mortality Following Breast Cancer Surgery in Women: National Benchmarks for Standards of Care , 2007, Annals of surgery.
[25] Michael Waller,et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial , 2006, The Lancet.
[26] Daniel B Kopans,et al. The 2009 U.S. Preventive Services Task Force guidelines ignore important scientific evidence and should be revised or withdrawn. , 2010, Radiology.
[27] A. M. Murphy. Mammography screening for breast cancer: a view from 2 worlds. , 2010, JAMA.
[28] Robert A Smith,et al. American Cancer Society guidelines for the early detection of cancer , 2000, CA: a cancer journal for clinicians.
[29] M. Gold,et al. Panel on cost-effectiveness in health and medicine. , 1996, Medical care.
[30] Mark A Helvie,et al. United States Preventive Services Task Force screening mammography recommendations: science ignored. , 2011, AJR. American journal of roentgenology.
[31] Joann G. Elmore,et al. Screening for breast cancer. , 1995, JAMA.
[32] Evette Ludman,et al. Quality of life valuations of mammography screening , 2008, Quality of Life Research.
[33] P. Glynn,et al. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. , 2006, Journal of the National Cancer Institute. Monographs.
[34] G J van Oortmarssen,et al. In search of the best upper age limit for breast cancer screening. , 1995, European journal of cancer.
[35] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[36] L. Tabár,et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. , 2000, Radiologic clinics of North America.
[37] L. Schwartz,et al. The benefits and harms of mammography screening: understanding the trade-offs. , 2010, JAMA.